Sintx Technologies, Inc.
Business
SINTX Technologies is an advanced ceramics company that develops, manufactures, and commercializes silicon nitride biomaterials, composites, and devices for medical and industrial applications. The company produces medical-grade silicon nitride in multiple forms—monolithic solids, porous structures, powders, and coatings—for spinal fusion implants, joint replacements, foot and ankle reconstruction, and antipathogenic applications including face masks and wound-care devices. SINTX operates an FDA-registered manufacturing facility in Salt Lake City and sells primarily in the United States, with products distributed through direct channels and OEM partnerships including CTL Medical.
Summary from 10-K filed 2026-03-20
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Total revenue | 1 | 3 | 3 | 2 | 606,000 | |
| Cost of revenue | 557,000 | 811,000 | 784,000 | 265,000 | 449,000 | |
| Gross profit | 461,000 | 2 | 2 | 1 | 157,000 | |
| Research and development | 5 | 5 | 9 | 6 | 6 | |
| General and administrative | 6 | 4 | 4 | 4 | 4 | |
| Sales and marketing | 242,000 | 614,000 | 1 | 1 | 1 | |
| Armor exit costs | — | 5 | — | — | — | |
| Reduction in force | — | 407,000 | — | — | — | |
| Grant and contract expenses | 156,000 | 1 | — | — | — | |
| Total operating expenses | 11 | 16 | 15 | 13 | 11 | |
| Loss from operations | −11 | −14 | −13 | −11 | −11 | |
| Interest expense | −52,000 | −29,000 | −2,000 | −17,000 | −25,000 | |
| Interest income | 175,000 | 107,000 | 135,000 | 23,000 | 101,000 | |
| Gain (loss) on the disposal of assets | 327,000 | −19,000 | 17,000 | −1,000 | 144,000 | |
| Change in fair value of derivative liabilities | −124,000 | 3 | 6 | −1 | — | |
| Offering costs of derivative liabilities | — | −550,000 | −786,000 | — | — | |
| Other income (expense) | 31,000 | 39,000 | 17,000 | 382,000 | 4,000 | |
| Total other income (expense), net | 357,000 | 3 | 5 | −704,000 | 1 | |
| Net loss before income taxes | −10 | −11 | −8 | −12 | −9 | |
| Provision for income taxes | — | — | — | — | — | |
| Net loss | −10 | −11 | −8 | −12 | −9 | |
| Deemed dividend related to warrant inducement | −7 | — | — | — | — | |
| Net loss attributable to common stockholders | −17 | −11 | −8 | −16 | −9 | |
| Basic net loss | −3.74 | −14.87 | −442.08 | −39.92 | — | |
| Basic deemed dividend related to warrant inducement | −2.42 | — | — | — | — | |
| Basic attributable to common stockholders | −6.16 | −14.87 | −443.47 | −54.67 | −37.7 | |
| Diluted net loss | −3.74 | −15.19 | −623.28 | −46.79 | — | |
| Diluted - deemed dividend related to warrant inducement | −2.42 | — | — | — | — | |
| Diluted attributable to common stockholders | −6.16 | −15.19 | −624.47 | −60.81 | −39.91 | |
| Basic | 3 | 741,250 | 18,682 | 301,610 | 246,919 | |
| Diluted | 3 | 744,782 | 21,786 | 317,323 | 250,701 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 4 | 4 | 3 | 6 | 14 | |
| Account and other receivables, net of allowance totaling $2.4 and $61.0 respectively | 178,000 | 196,000 | 685,000 | 328,000 | 102,000 | |
| Prepaid expenses and other current assets | 507,000 | 225,000 | 539,000 | 344,000 | 350,000 | |
| Inventories | 825,000 | 502,000 | 888,000 | — | — | |
| Total current assets | 6 | 5 | 6 | 7 | 15 | |
| Inventories, net | 219,000 | 465,000 | 333,000 | 453,000 | 294,000 | |
| Property and equipment, net | 476,000 | 922,000 | 5 | 6 | 4 | |
| Intangible assets, net | 142,000 | 16,000 | 21,000 | 26,000 | 31,000 | |
| Goodwill | 302,000 | — | — | — | — | |
| Operating lease right of use asset | 3 | 3 | 4 | 2 | 2 | |
| Other long-term assets | 259,000 | 330,000 | 559,000 | 85,000 | 77,000 | |
| Total assets | 10 | 9 | 15 | 16 | 22 | |
| Accounts payable | 382,000 | 299,000 | 636,000 | 434,000 | 241,000 | |
| Accrued liabilities | 422,000 | 986,000 | 1 | 2 | 1 | |
| Debt | 7,000 | 32,000 | 46,000 | 160,000 | 509,000 | |
| Derivative liabilities | 827,000 | 208,000 | 304,000 | 5 | 347,000 | |
| Current portion of operating lease liability | 398,000 | 456,000 | 512,000 | 738,000 | 500,000 | |
| Other current liabilities | 2 | 1,000 | 4,000 | 2,000 | — | |
| Total current liabilities | 4 | 2 | 3 | 8 | 3 | |
| Operating lease liability, net of current portion | 3 | 4 | 4 | 2 | 2 | |
| Total liabilities | 7 | 6 | 7 | 10 | 5 | |
| Commitments and contingencies | — | — | — | — | — | |
| Treasury stock, 50,424 shares as of December 31, 2025 | −133,000 | — | — | — | — | |
| Common stock, $0.01 par value, 250,000,000 shares authorized; 3,970,869 and 1,342,853 shares issued and outstanding as of December 31, 2025 and 2024, respectively. | 40,000 | 13,000 | — | 5,000 | 2,000 | |
| Additional paid-in capital | 295 | 286 | 279 | 268 | 268 | |
| Accumulated deficit | −292 | −282 | −271 | −263 | −250 | |
| Total stockholders equity | 3 | 4 | 9 | 6 | 17 | |
| Total liabilities and stockholders equity | 10 | 9 | 15 | 16 | 22 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation expense | 300,000 | 800,000 | 900,000 | 300,000 | 200,000 | |
| Amortization of right of use asset | 324,000 | 537,000 | 745,000 | 623,000 | — | |
| Amortization of intangible assets | 19,000 | 5,000 | 5,000 | 5,000 | 5,000 | |
| Loss on disposal of subsidiary | 25,000 | — | — | — | — | |
| Impairment of Armor | 64,000 | 5 | — | — | — | |
| Stock based compensation Employee | 1 | 82,000 | 291,000 | 369,000 | 309,000 | |
| Stock based compensation Non-employee | 606,000 | — | — | — | — | |
| Change in fair value of derivative liabilities | 124,000 | −3 | −6 | 1 | — | |
| Loss (gain) on disposal of equipment | −352,000 | 18,000 | −17,000 | 1,000 | −144,000 | |
| Bad debt expense (recoveries) | −3,000 | −1,000 | — | −7,000 | — | |
| Account and other receivables | −69,000 | 490,000 | −420,000 | −26,000 | −61,000 | |
| Prepaid expenses and other assets | −47,000 | 482,000 | −264,000 | 13,000 | −149,000 | |
| Inventories | −85,000 | 72,000 | −485,000 | −140,000 | −110,000 | |
| Accounts payable and accrued liabilities | −200,000 | −756,000 | −12,000 | 226,000 | 264,000 | |
| Other liabilities | 45,000 | −2,000 | −370,000 | −128,000 | −26,000 | |
| Payments on operating lease liability | −367,000 | −514,000 | −689,000 | −586,000 | −401,000 | |
| Net cash used in operating activities | −9 | −9 | −14 | −10 | −10 | |
| Purchase of property and equipment | −185,000 | −690,000 | −530,000 | −1 | −4 | |
| Disposal of property and equipment, net of cash received | −4,000 | — | — | — | — | |
| Proceeds from the sale of property and equipment | 352,000 | 20,000 | 29,000 | 1,000 | 144,000 | |
| Proceeds from acquisition of Sinaptic Surgical | 750,000 | — | — | — | — | |
| Proceeds from notes receivable, net of imputed interest | — | 476,000 | — | — | — | |
| Net cash provided by (used in) investing activities | 913,000 | −194,000 | −501,000 | −1 | −2 | |
| Proceeds from issuance of warrant derivative liabilities | — | 3 | 7 | — | — | |
| Proceeds from issuance of common stock and prefunded warrants, net of cash fees | 4 | 6 | 5 | — | — | |
| Proceeds from exercise of warrants, net of cash fees, and deposit for stock issuance (in other current liabilities) | 4 | — | — | — | — | |
| Proceeds from issuance of common stock in connection with ATM, net of fees | 329,000 | — | — | — | — | |
| Proceeds from issuance of warrants in connection with exercise of warrants | 206,000 | — | — | — | 196,000 | |
| Purchase of common stock into treasury | −133,000 | — | — | — | — | |
| Proceeds from issuance of common stock in connection with exercise of warrants | — | 2,000 | — | — | — | |
| Principal payment on debt | −206,000 | −349,000 | −114,000 | −509,000 | — | |
| Net cash provided by financing activities | 8 | 9 | 12 | 3 | 705,000 | |
| Net increase in cash and cash equivalents | 542,000 | 258,000 | −3 | −8 | −11 | |
| Reduction of derivative liability upon exercise of warrants | — | 1,000 | 6 | — | — | |
| Deemed dividend related to warrant inducement and issuance of warrants | 7 | — | — | — | — | |
| Right of use asset for amended lease liability decrease | — | 307,000 | −89,000 | — | — | |
| Debt issued for prepaid insurance | 180,000 | 335,000 | — | — | — | |
| Agent warrant offering cost allocated to equity | — | 13,000 | — | — | — | |
| Cash paid for interest | 52,000 | 29,000 | 21,000 | 1,000 | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Sintx Technologies, Inc.'s CIK number?
Sintx Technologies, Inc.'s SEC CIK number is 0001269026 (1269026). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Sintx Technologies, Inc.'s SEC filings?
All of Sintx Technologies, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Sintx Technologies, Inc. last report earnings?
Sintx Technologies, Inc. (SINT) most recently filed an earnings 8-K with the SEC on Nov 13, 2025, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001493152-25-022125). This is Sintx Technologies, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Sintx Technologies, Inc.'s most recent earnings 8-K?
Sintx Technologies, Inc.'s latest earnings 8-K (Item 2.02) was filed Nov 13, 2025 under accession 0001493152-25-022125. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Sintx Technologies, Inc.'s latest earnings 8-K →
Look up any company's CIK number →